Patents Examined by Michael C. Henry
  • Patent number: 11576924
    Abstract: Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 14, 2023
    Inventors: Eliezer Zomer, Peter G. Traber, Raphael Nir, Sharon Shechter, Joseph M. Johnson, Ryan George
  • Patent number: 11566040
    Abstract: Disclosed is synthesis of an O-Antigen oligosaccharide compound of Helicobacter pylori serotype O2, belonging to the field of organic synthesis. The disclosure obtains O-antigen disaccharide to tetracosasaccharide of Helicobacter pylori serotype O2 by chemical synthesis. A chemical synthesis method which is quite conducive to production of a glucose-?-lglucosidic bond is developed in the disclosure by a protectant strategy, temperature effect, solvent effect, and additive effect. The method is applied in synthesis of an O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm. A saccharide conjugate can be prepared from the synthesized O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm together with a carrier protein for immunology researches, playing an important role in preventing and treating Helicobacter pylori.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: January 31, 2023
    Assignee: Jiangnan University
    Inventors: Jian Yin, Jing Hu, Zhonghua Liu, Chunjun Qin
  • Patent number: 11549001
    Abstract: A malto-dextrin composition with low DE value and low viscosity and the method for making the same is provided. The malto-dextrin comprises a blue value in the range of 0.02 to 0.28; a dextrose equivalent (DE) in the range of 3 to 10; and a viscosity lower than 26.3185*DE{circumflex over (?)}(?0.7593). The method for preparing the malto-dextrin composition comprises: dispersing raw starch in water to obtain a starch-water slurry; preheating the starch-water slurry with a jet-cooker for a first duration at a first temperature above 100° C. having a temperature variation no more than 0.8° C.; hydrolyzing the slurry by treating the slurry with ?-amylases for a second duration at a second temperature; and filtering the hydrolyzed slurry to remove insoluble residual proteins and fibers and obtain an un-fractionated malto-dextrin composition.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: January 10, 2023
    Inventors: Loren Chen, Yi Cai
  • Patent number: 11529364
    Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Glycom A/S
    Inventors: Emma Elison, Bruce McConnell, Thierry Hennet, Louise Kristine Vigsnæs
  • Patent number: 11529365
    Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 20, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 11497763
    Abstract: A compound that includes a dextran backbone having at least one C-type lectin targeting moieties attached thereto. Also disclosed are embodiments of the compound that include at least one therapeutic agent and/or at least one detection label attached to the dextran backbone. The compound may be effective for treatment of Corona Covid-19 (SARS-covid-2) virus, its variants and other related viral diseases, and disorders. Further disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: November 15, 2022
    Assignee: Physis International LLC
    Inventor: Frederick Oliver Cope
  • Patent number: 11491178
    Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: November 8, 2022
    Inventors: Jayne Chin, Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Achyutharao Sidduri
  • Patent number: 11491181
    Abstract: The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.
    Type: Grant
    Filed: July 15, 2017
    Date of Patent: November 8, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Sungwhan Oh, Deniz Erturk-Hasdemir, Dennis L. Kasper, Kailyn L. Stefan
  • Patent number: 11491237
    Abstract: Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: November 8, 2022
    Inventors: Amy Han, William Olson
  • Patent number: 11478494
    Abstract: The present invention provides compositions and methods for the treatment of neurological disorders. In particular, the present invention can be used for treating and/or preventing the symptoms and/or comorbidities of neurodegenerative conditions, diseases or disorders, such as, for example, Alzheimer's and Parkinson's disease.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: October 25, 2022
    Inventors: Sean Farmer, Ken Alibek, Alibek Moldakozhayev, Albina Tskhay
  • Patent number: 11479616
    Abstract: An okra polygalacturonic acid having a uric acid-lowering effect, a method for preparing the same, and use of the same are disclosed. The method includes: smashing an okra, lixiviating the okra in ethanol, and filtering to obtain a filtrate and a residue; removing the filtrate, and lixiviating the residue in heated water to obtain an extraction solution; adding the ethanol into the extraction solution to precipitate okra crude polysaccharides; purifying the okra crude polysaccharides over an anion exchange column by eluting with water or a NaCl solution, a Tris-HCl solution or a NaCl-containing Tris-HCl solution, or a phosphate solution or a NaCl-containing phosphate solution, and collecting a fraction eluted by the NaCl solution, the NaCl-containing Tris-HCl solution, or the NaCl-containing phosphate solution; and concentrating, dialyzing and drying the fraction to obtain the okra polygalacturonic acid.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: October 25, 2022
    Assignee: Institute of Biological and Medical Engineering, Guangdong Academy of Sciences
    Inventors: Juan Liu, Junjia Chen, Chuanli Lu, Nianfang Ma, Peizi Kang
  • Patent number: 11471451
    Abstract: The present invention includes methods of monitoring measurable residual disease in patients suffering from a proliferative disorder, determining which patients could benefit from treatment or intervention with crenolanib or salt in reducing residual disease and maintaining remission, and administering a therapeutically effective amount of crenolanib as a single agent or sequentially or concomitantly with another therapeutic agent.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: October 18, 2022
    Inventor: Vinay K. Jain
  • Patent number: 11466045
    Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: October 11, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Jon S. Thorson, Jurgen Rohr, Markos Leggas, Joseph M. Eckenrode, Yinan Zhang, Yang Liu, Jianjun Zhang, Khaled Attia Shaaban Mahmoud
  • Patent number: 11433087
    Abstract: The disclosure provides a CD169 high affinity anti-tumor compound (TCC-Neu5A) and its preparation and application. The CD169 high affinity anti-tumor compound is a small molecule compound, which has specific and broad-spectrum tumor killing characteristics. TCC-Neu5Ac could targets tumor cells in vivo and metabolize onto a surface of the tumor cells to form CD169 ligands. These tumor cells are recognized and phagocytized by CD169-positive macrophages, which then release tumor-related antigens and present them to other immune cells, triggering an anti-tumor immune response. The CD169 high affinity anti-tumor compound provided by the disclosure is effective for a variety of tumors and has an inhibitory effect on tumor metastasis. In addition, the CD169 high affinity anti-tumor compound provided by the disclosure can not only be injected but also be orally administered. Cytotoxicity and animal toxicity of the CD169 high affinity anti-tumor compound are very low.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 6, 2022
    Assignee: Xiamen Nuokangde Biological Technology Co., Ltd.
    Inventors: Xu Yan, Xuchun Han, Xianwu Wang
  • Patent number: 11434480
    Abstract: The present invention relates to a composition for viral RNA extraction and a viral RNA extraction method using the same, wherein various contaminants (e.g., fungi, bacteria, pollens, etc.) can be effectively removed from samples and thus the diagnosis of sample-derived viruses can be attained more sensitively, and more cheap reagents compared with existing compositions for RNA extraction are used and thus the scales of diagnosis tests of disease-mediated viruses and various monitoring programs can be further enlarged, thereby contributing to public health.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 6, 2022
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Ki Beom Park, Yong Hun Jo, Yeon Soo Han
  • Patent number: 11421047
    Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 23, 2022
    Assignee: Bausch & Lomb Incorporated
    Inventors: George L. Grobe, III, Alok Kumar Awasthi, Mark R. Mis, Jennah L. Wolcott, James R. Hauenstein
  • Patent number: 11413303
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: August 16, 2022
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Patent number: 11407781
    Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: August 9, 2022
    Assignee: Graybug Vision, Inc.
    Inventors: Hans-Gottfried Genieser, Frank Schwede, Andreas Rentsch, Per Ekström, Valeria Marigo, Francois Paquet-Durand
  • Patent number: 11389465
    Abstract: The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 19, 2022
    Assignee: Vanderbilt University
    Inventors: Edward Sherwood, Antonio Hernandez, Julia Bohannon
  • Patent number: 11382883
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 12, 2022
    Inventors: James J. Collins, Sylvain Meylan, Samuel Moskowitz